Tissue Repair Ltd (AU:TRP) has released an update.
Tissue Repair Ltd has achieved a significant milestone by securing Listed Medicine status with the TGA for Glucoprime®, with a PR launch planned for Q1 2025, allowing the company to make healing claims and expand marketing. The company is also set to file a device application in the US for Glucoprime® as a skin substitute, aiming to penetrate the market before drug approval. Additionally, Tissue Repair Ltd reported a 100% sales growth for TR Pro+™ over the previous quarter, with strong product effectiveness feedback and sales reaching approximately $26k per month across numerous clinics.
For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.